Future Treatments of NASH

Current Hepatology Reports

Volumn 15, Issue 2, 2016, Pages 125-133

  Neuschwander Tetri, Brent A ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti fibrotic; De novo lipogenesis; Lipotoxicity; Nonalcoholic steatohepatitis (NASH); Obeticholic acid; Vitamin E

Indexed keywords

EID: 85016988477     PISSN: None     EISSN: 21959595     Source Type: Journal    
DOI: 10.1007/s11901-016-0300-3     Document Type: Article

References (69)

1. J.E. Schaffer Lipotoxicity: when tissues overeat Curr Opin Lipidol 2003 14 281 7 1:CAS:528:DC%2BD3sXktlOjurw%3D 10.1097/00041433-200306000-00008 12840659
2. H. Malhi G.J. Gores Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease Semin Liver Dis 2008 28 360 9 1:CAS:528:DC%2BD1cXhsVKju7fF 10.1055/s-0028-1091980 18956292 2908270
3. B.A. Neuschwander-Tetri Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites Hepatology 2010 52 774 88 10.1002/hep.23719 20683968
4. M. Trauner M. Arrese M. Wagner Fatty liver and lipotoxicity Biochim Biophys Acta 1801 2010 299 310
5. K. Cusi Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications Gastroenterology 2012 142 711 25 1:CAS:528:DC%2BC38XltVyrsLs%3D 10.1053/j.gastro.2012.02.003 22326434
6. A.K. Leamy R.A. Egnatchik J.D. Young Molecular mechanisms and the role of saturated fatty acids in the progression of non-alcoholic fatty liver disease Prog Lipid Res 2013 52 165 74 1:CAS:528:DC%2BC3sXovFWlsg%3D%3D 10.1016/j.plipres.2012.10.004 23178552
7. C.P. Day O.F. James Steatohepatitis: a tale of two “hits”? Gastroenterology 1998 114 842 5 1:STN:280:DyaK1c3htFartQ%3D%3D 10.1016/S0016-5085(98)70599-2 9547102
8. C.P. Day O.F. James Hepatic steatosis: innocent bystander or guilty party? Hepatology 1998 27 1463 6 1:STN:280:DyaK1c3otFKhtg%3D%3D 10.1002/hep.510270601 9620314
9. P. Angulo D.E. Kleiner S. Dam-Larsen et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease Gastroenterology 2015 149 389 97 10.1053/j.gastro.2015.04.043 25935633
10. G. Lassailly R. Caiazzo D. Buob et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients Gastroenterology 2015 149 379 88 10.1053/j.gastro.2015.04.014 25917783
11. V. Ratziu S. Harrison S. Francque et al. Elafibranor, an agonist of the peroxisome proliferator−activated receptor−α and −δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening Gastroenterology 2016 26874076 Randomized clinical trial demonstrating a benefit of elafibranor. The benefit appeared more in those with advanced disease.
12. B. Cariou R. Hanf S. Lambert-Porcheron et al. Dual peroxisome proliferator-activated receptor α/δ agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects Diabetes Care 2013 36 2923 30 1:CAS:528:DC%2BC3sXhs1ylt7vI 10.2337/dc12-2012 23715754 3781493
13. L.A. Bojic M.W. Huff Peroxisome proliferator-activated receptor δ: a multifaceted metabolic player Curr Opin Lipidol 2013 24 171 7 1:CAS:528:DC%2BC3sXjvVeju70%3D 10.1097/MOL.0b013e32835cc949 23481229
14. U. Risérus D. Sprecher T. Johnson et al. Activation of peroxisome proliferator-activated receptor (PPAR)δ promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men Diabetes 2008 57 332 9 10.2337/db07-1318 18024853
15. N. Stefan C. Thamer H. Staiger et al. Genetic variations in PPARD and PPARGC1A determine mitochondrial function and change in aerobic physical fitness and insulin sensitivity during lifestyle intervention J Clin Endocrinol Metab 2007 92 1827 33 1:CAS:528:DC%2BD2sXlt1Oktb8%3D 10.1210/jc.2006-1785 17327385
16. L. Sidossis S. Kajimura Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis J Clin Invest 2015 125 478 86 10.1172/JCI78362 25642708 4319444
17. R. Xue M.D. Lynes J.M. Dreyfuss et al. Clonal analyses and gene profiling identify genetic biomarkers of the thermogenic potential of human brown and white preadipocytes Nat Med 2015 21 760 8 1:CAS:528:DC%2BC2MXhtFeisrrL 10.1038/nm.3881 26076036 4496292
18. K. Shinoda I.H. Luijten Y. Hasegawa et al. Genetic and functional characterization of clonally derived adult human brown adipocytes Nat Med 2015 21 389 94 1:CAS:528:DC%2BC2MXkvFejtrs%3D 10.1038/nm.3819 25774848 4427356
19. A. Bartelt O.T. Bruns R. Reimer et al. Brown adipose tissue activity controls triglyceride clearance Nat Med 2011 17 200 5 1:CAS:528:DC%2BC3MXps1aisw%3D%3D 10.1038/nm.2297 21258337
20. S.P. Rajeev D.J. Cuthbertson J.P. Wilding Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition Diabetes Obes Metab 2016 18 125 34 1:CAS:528:DC%2BC28Xhs1Kiurw%3D 10.1111/dom.12578 26403227
21. J.L. Trevaskis P.S. Griffin C. Wittmer et al. Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice Am J Physiol Gastrointest Liver Physiol 2012 302 G762 72 1:CAS:528:DC%2BC38Xmsl2gurg%3D 10.1152/ajpgi.00476.2011 22268099
22. M.J. Armstrong P. Gaunt G.P. Aithal et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study Lancet 2016 387 679 90 1:CAS:528:DC%2BC2MXhvVygsbzK 10.1016/S0140-6736(15)00803-X 26608256 Recent small randomized clinical trial showing a significant beneficial effect of the GLP-1 analogue liraglutide on the resolution of NASH.
23. J.J. Liu J.P. Foo S. Liu et al. The role of fibroblast growth factor 21 in diabetes and its complications: a review from clinical perspective Diabetes Res Clin Pract 2015 108 382 9 1:CAS:528:DC%2BC2MXktVKht7s%3D 10.1016/j.diabres.2015.02.032 25796513
24. S. Dasarathy Y. Yang A.J. McCullough et al. Elevated hepatic fatty acid oxidation, high plasma fibroblast growth factor 21, and fasting bile acids in nonalcoholic steatohepatitis Eur J Gastroenterol Hepatol 2011 23 382 8 1:CAS:528:DC%2BC3MXks1Whsrc%3D 10.1097/MEG.0b013e328345c8c7 21448070 3493151
25. S.L. Samson P. Sathyanarayana M. Jogi et al. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial Diabetologia 2011 54 3093 100 1:CAS:528:DC%2BC3MXhsVGgu7vE 10.1007/s00125-011-2317-z 21956711 3658171
26. M. Trauner T. Claudel P. Fickert et al. Bile acids as regulators of hepatic lipid and glucose metabolism Dig Dis 2010 28 220 4 10.1159/000282091 20460915
27. B. Cariou E. Bouchaert M. Abdelkarim et al. FXR-deficiency confers increased susceptibility to torpor FEBS Lett 2007 581 5191 8 1:CAS:528:DC%2BD2sXht1Krtb7N 10.1016/j.febslet.2007.09.064 17950284
28. P. Lefebvre B. Cariou F. Lien et al. Role of bile acids and bile acid receptors in metabolic regulation Physiol Rev 2009 89 147 91 1:CAS:528:DC%2BD1MXit1Cqtro%3D 10.1152/physrev.00010.2008 19126757
29. J.S. Teodoro A.P. Rolo C.M. Palmeira Hepatic FXR: key regulator of whole-body energy metabolism Trends Endocrinol Metab 2011 22 458 66 1:CAS:528:DC%2BC3MXhtl2iurrP 10.1016/j.tem.2011.07.002 21862343
30. H.A. Cyphert X. Ge A.B. Kohan et al. Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21 J Biol Chem 2012 287 25123 38 1:CAS:528:DC%2BC38XhtVGnt7vO 10.1074/jbc.M112.375907 22661717 3408207
31. C. Thomas A. Gioiello L. Noriega et al. TGR5-mediated bile acid sensing controls glucose homeostasis Cell Metab 2009 10 167 77 1:CAS:528:DC%2BD1MXhsVChtLnM 10.1016/j.cmet.2009.08.001 19723493 2739652
32. M. Watanabe S.M. Houten C. Mataki et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation Nature 2006 439 484 9 1:CAS:528:DC%2BD28XntFWmuw%3D%3D 10.1038/nature04330 16400329
33. B.A. Neuschwander-Tetri R. Loomba A.J. Sanyal et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial Lancet 2015 385 956 65 1:CAS:528:DC%2BC2cXhvV2gtr%2FE 10.1016/S0140-6736(14)61933-4 25468160 4447192 Randomized clinical trial showing that the FXR ligand obeticholic acid improved NASH in some patients but was accompanied by elevations in total and HDL cholesterol.
34. M.D. Erion E.E. Cable B.R. Ito et al. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index Proc Natl Acad Sci U S A 2007 104 15490 5 1:CAS:528:DC%2BD2sXhtFajs7jF 10.1073/pnas.0702759104 17878314 1978486
35. E.E. Cable P.D. Finn J.W. Stebbins et al. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist Hepatology 2009 49 407 17 1:CAS:528:DC%2BD1MXivFWhtrw%3D 10.1002/hep.22572 19072834
36. R.J. Perry T. Kim X.M. Zhang et al. Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler Cell Metab 2013 18 740 8 1:CAS:528:DC%2BC3sXhslertb3F 10.1016/j.cmet.2013.10.004 24206666 4104686
37. R.J. Perry D. Zhang X.M. Zhang et al. Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats Science 2015 347 1253 6 1:CAS:528:DC%2BC2MXjvFyksL8%3D 10.1126/science.aaa0672 25721504 4495920
38. E. Yehuda-Shnaidman B. Kalderon J. Bar-Tana Thyroid hormone, thyromimetics, and metabolic efficiency Endocr Rev 2014 35 35 58 1:CAS:528:DC%2BC2cXls1Whs74%3D 10.1210/er.2013-1006 23970761
39. K.L. Donnelly C.I. Smith S.J. Schwarzenberg et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease J Clin Invest 2005 115 1343 51 1:CAS:528:DC%2BD2MXktFSktLk%3D 10.1172/JCI23621 15864352 1087172
40. M.K. Pickens J.S. Yan R.K. Ng et al. Dietary sucrose is essential to the development of liver injury in the methionine-choline-deficient model of steatohepatitis J Lipid Res 2009 50 2072 82 1:CAS:528:DC%2BD1MXhtF2qsLnF 10.1194/jlr.M900022-JLR200 19295183 2739762
41. M.K. Pickens H. Ogata R.K. Soon et al. Dietary fructose exacerbates hepatocellular injury when incorporated into a methionine-choline-deficient diet Liver Int 2010 30 1229 39 1:CAS:528:DC%2BC3cXhtFKkurbK 10.1111/j.1478-3231.2010.02285.x 20536716 3592570
42. R. Safadi F.M. Konikoff M. Mahamid et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease Clin Gastroenterol Hepatol 2014 12 2085 91 1:CAS:528:DC%2BC2cXhtFWisL7F 10.1016/j.cgh.2014.04.038 24815326
43. M.T. Flowers A.K. Groen A.T. Oler et al. Cholestasis and hypercholesterolemia in SCD1-deficient mice fed a low-fat, high-carbohydrate diet J Lipid Res 2006 47 2668 80 1:CAS:528:DC%2BD28XhtlSit7fO 10.1194/jlr.M600203-JLR200 17005996
44. A.J. Sanyal N. Chalasani K.V. Kowdley et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 2010 362 1675 85 1:CAS:528:DC%2BC3cXls1Oltr4%3D 10.1056/NEJMoa0907929 20427778 2928471 The PIVENS trial demonstrated improvement in NASH with pioglitazone but with weight gain in some patients. Vitamin E also resulted in improvement in some patients.
45. V. Ratziu F. Charlotte C. Bernhardt et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial Hepatology 2010 51 445 53 1:CAS:528:DC%2BC3cXisVGgurg%3D 10.1002/hep.23270 19877169
46. L.N. Bell J. Wang S. Muralidharan et al. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study Hepatology 2012 56 1311 8 1:CAS:528:DC%2BC38XhsVKmurzE 10.1002/hep.25805 22532269 3432683
47. A. Iyer D.P. Fairlie J.B. Prins et al. Inflammatory lipid mediators in adipocyte function and obesity Nat Rev Endocrinol 2010 6 71 82 1:CAS:528:DC%2BC3cXpslCqsQ%3D%3D 10.1038/nrendo.2009.264 20098448
48. K. Yamaguchi L. Yang S. McCall et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis Hepatology 2007 45 1366 74 1:CAS:528:DC%2BD2sXnvFaltLw%3D 10.1002/hep.21655 17476695
49. K.D. Lindor K.V. Kowdley E.J. Heathcote et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial Hepatology 2004 39 770 8 1:CAS:528:DC%2BD2cXjtlaiu78%3D 10.1002/hep.20092 14999696
50. A.J. Sanyal M.F. Abdelmalek A. Suzuki et al. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial Gastroenterology 2014 147 377 84 1:CAS:528:DC%2BC2cXhtFyhur3M 10.1053/j.gastro.2014.04.046 24818764 No benefit from treatment with this polyunsaturated fatty acid ethyl ester in a large multicenter controlled trial.
51. Lirussi F, Azzalini L, Orando S, et al. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 2007;4. doi:10.1002/14651858.CD004996.pub3.
52. L.N. Bell J.P. Molleston M.J. Morton et al. Hepatic lipid peroxidation and cytochrome P-450 2E1 in pediatric nonalcoholic fatty liver disease and its subtypes J Clin Gastroenterol 2011 45 800 7 1:CAS:528:DC%2BC3MXhtFymtb7E 10.1097/MCG.0b013e31821377e4 21602702
53. J.E. Lavine J.B. Schwimmer M.L. Van Natta et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial JAMA 2011 305 1659 68 1:CAS:528:DC%2BC3MXlsVyit7Y%3D 10.1001/jama.2011.520 21521847 3110082 Randomized clinical trial demonstrating the effect of vitamin E in children.
54. M.F. Abdelmalek S.O. Sanderson P. Angulo et al. Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial Hepatology 2009 50 1818 26 1:CAS:528:DC%2BD1MXhs1SjurvI 10.1002/hep.23239 19824078
55. Q.M. Anstee C.P. Day S-adenosylmethionine (SAMe) therapy in liver disease: a review of current evidence and clinical utility J Hepatol 2012 57 1097 109 1:CAS:528:DC%2BC38XhsFKlurjN 10.1016/j.jhep.2012.04.041 22659519
56. P. Puri R.A. Baillie M.M. Wiest et al. A lipidomic analysis of nonalcoholic fatty liver disease Hepatology 2007 46 1081 90 1:CAS:528:DC%2BD2sXht1aksr3F 10.1002/hep.21763 17654743
57. A. Abu-Shanab E.M. Quigley The role of the gut microbiota in nonalcoholic fatty liver disease Nat Rev Gastroenterol Hepatol 2010 7 691 701 10.1038/nrgastro.2010.172 21045794
58. A.E. Feldstein Novel insights into the pathophysiology of nonalcoholic fatty liver disease Semin Liver Dis 2010 30 391 401 1:CAS:528:DC%2BC3cXhsFaksbfL 10.1055/s-0030-1267539 20960378
59. C. Savard E.V. Tartaglione R. Kuver et al. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis Hepatology 2013 57 81 92 1:CAS:528:DC%2BC3sXms12isw%3D%3D 10.1002/hep.25789 22508243
60. Lanaspa MA, Sanchez-Lozada LG, Cicerchi C, et al. Uric acid stimulates fructokinase and accelerates fructose metabolism in the development of fatty liver. PLoS ONE. 2012;7:e47948. doi:10.1371/journal.pone.0047948
61. G. Szabo J. Petrasek Inflammasome activation and function in liver disease Nat Rev Gastroenterol Hepatol 2015 12 387 400 1:CAS:528:DC%2BC2MXhtFKktbrN 10.1038/nrgastro.2015.94 26055245
62. A. Wree W.Z. Mehal A.E. Feldstein Targeting cell death and sterile inflammation loop for the treatment of nonalcoholic steatohepatitis Semin Liver Dis 2016 36 27 36 1:CAS:528:DC%2BC28XisV2ru7Y%3D 10.1055/s-0035-1571272 26870930
63. M.V. Machado A.M. Diehl Pathogenesis of nonalcoholic steatohepatitis Gastroenterology 2016 26928243 Excellent update on how the reponse to lipotoxic injury plays a role in the outcome.
64. Ratziu V, Bedossa P, Francque SM, et al. Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2014;12:1724–30 e5. A potent antiinflammatory phosphodiesterase-4 inhibitor did not improve NASH.
65. C.O. Zein L.M. Yerian P. Gogate et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial Hepatology 2011 54 1610 9 1:CAS:528:DC%2BC3MXhtlygsbrI 10.1002/hep.24544 21748765 3205292
66. L.B. Van Wagner S.W.P. Koppe E.M. Brunt et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial Ann Hepatol 2011 10 277 86 21677329
67. V. Ratziu M.Y. Sheikh A.J. Sanyal et al. A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis Hepatology 2012 55 419 28 1:CAS:528:DC%2BC38Xht1yqtbo%3D 10.1002/hep.24747 22006541 3779694
68. F.J. Barreyro S. Holod P.V. Finocchietto et al. The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis Liver Int 2015 35 953 66 1:CAS:528:DC%2BC2MXivVehsbg%3D 10.1111/liv.12570 24750664
69. Traber PG, Zomer E. Therapy of experimental NASH and fibrosis with galectin inhibitors. PLoS ONE. 2013;8:e83481. doi:10.1371/journal.pone.0083481